Michael King - Feb 21, 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Michael G. King, Jr.
Stock symbol
SABS
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 04:45 PM
Previous filing
Nov 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +115K $0.00 115K Feb 21, 2024 Common Stock 115K $5.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2014 Equity Incentive Plan.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.